|Bid||3.0600 x 2200|
|Ask||3.1400 x 800|
|Day's Range||3.0165 - 3.1400|
|52 Week Range||2.3404 - 6.5957|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||3.05|
|Earnings Date||Aug 12, 2019 - Aug 16, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Agreement to Acquire Assets of CBM BioPharma, Inc. In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
ORLANDO, FL / ACCESSWIRE / April 10, 2019 / In today's issue of SmalCap Sentinel, we get the opportunity to virtually sit down with Spherix Incorporated (SPEX) CEO, Anthony Hayes. It has been an eventful year for Hayes and Spherix, much of which Hayes covered in a wide-ranging recent shareholderletter.
ORLANDO, FL / ACCESSWIRE / April 3, 2019 / By any measure, Spherix Incorporated (NASDAQ: SPEX) has had a very good year. It is not often one can say at their annual meeting that the Company posted a one-time gain of $7.5 million and p.s., our science looks like it restored mobility to a mouse paralyzed by Acute Lymphoblastic Leukemia. With Spherix now booking total assets of $13.3 million, less than 9 million shares outstanding and zero debt, CEO Anthony Hayes has likely engendered some goodwill from his shareholder base.
One of the most challenging tasks as CEO is taking the vision of the Board and transferring that into meaningful value for our shareholders. However, 2018 marked a pivotal year for our Company as we forged ahead with the vision of creating an exciting biotechnology company. With more than $13,000,000 in assets and less than 9,000,000 in outstanding shares, we are moving Spherix in the right direction. The CBM transaction, announced in October of last year, brings to Spherix exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. Significant progress has already been made.
ORLANDO, FL / ACCESSWIRE / March 13, 2019 / In the world of smaller equities, revenue, especially for emerging biotech or tech companies, can be fleeting, rare even. As such, Spherix Incorporated (SPEX) posting a one-time gain of $7.5 million in its 10-K should turn a few heads. It is notable that the $7.5 million one-time gain comes from an investment the Company and Spherex CEO Anthony Hayes made two years ago, putting $670k into a then private biotech called Hoth Therapeutics where Hayes saw potential and promise.
NEW YORK , March 12, 2019 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX)- a technology development company committed to the fostering of innovative ideas, announced today that it has filed its Annual ...
NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA). PDA is considered the deadliest of major cancers and patients are in desperate need of improved therapies. PDA is caused by chronic inflammatory stress associated with the increasingly common afflictions of obesity, type 2 diabetes, and pancreatitis, exacerbated by smoking and drinking. KPC34 is a candidate therapeutic because it is activated preferentially inside tumor cells to release an inhibitor of DNA replication and a separate tumor promotion inhibitor. Annually, more than 350,000 new cases of pancreatic cancer are diagnosed across the world. According to the American Society of Clinical Oncology, a six-month course of gemcitabine, the chemotherapy drug typically used to treat advanced pancreatic cancer, costs about $23,500.
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Twilio shares were on the rise on an “outperform” rating reiterated from an Oppenheimer analyst last week while Spherix Incorporated shares popped on news ...
From renting out an unused road bike, to running a fleet of hundreds of electric scooters, Mellow provides a flexible entry for anyone interested in the growing shared vehicles space. Additional information about the investment will be available in the Form 8-K, filed by Spherix with the Securities and Exchange Commission.
NEW YORK, Oct. 29, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area. Dr. Rana Quraishi is the Director of New Ventures, at UM Ventures University of Maryland, Baltimore. UM Ventures is a joint initiative bringing the University of Maryland, Baltimore and University of Maryland, College Park together to commercialize discoveries and create economic impact by engaging partners in industry and social ventures. Dr. Quraishi has a Ph.D. in Molecular Biology and Biochemistry from Columbia University where she was also an undergraduate and an M.S. from Harvard University.
Las Vegas, Nevada--(Newsfile Corp. - October 25, 2018) - Early stage biotechnology and pharmaceutical companies often present a quandary for investors. The technology is generally difficult to understand and investors just can't fully picture the potential.Except when that picture is an absolutely stunning, must-see video from Wake Forest University of a mouse paralyzed by Acute Lymphoblastic Leukemia restored to mobility in two days by a drug now headed to the patent portfolio of ...
Anthony Hayes, CEO of Spherix, stated, "This remarkable video demonstrates the tremendous potential for this drug to treat ALL. The video was part of a written submission on KPC34 to PLOS OneTM a peer reviewed medical journal.
NEW YORK, Oct. 11, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has entered into a merger agreement with CBM BioPharma, Inc. ("CBM") that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion dollar oncology therapeutics market. CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
NEW YORK, Aug. 15, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced it has terminated its merger agreement with DatChat. After strategic meetings with DatChat, both organziations believe there is a more effective strategy that will have the best opportunity for long-term growth. The Spherix Board of Directors determined that a strategic equity investment in DatChat will provide a better strategy for shareholders and allow Spherix to benefit from DatChat's platform and projected growth.
Stock Research Monitor: ONE, SPEX, and TISI LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on MCO sign up now at www.wallstequities.com/registration . WallStEquities.com has ...
For Spherix Incorporated’s (NASDAQ:SPEX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. SPEX is exposed toRead More...
In this article, I’m going to take a look at Spherix Incorporated’s (NASDAQ:SPEX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...